News AstraZeneca PLC Xetra

Stocks

ZEG

GB0009895292

Pharmaceuticals

Real-time Estimate Tradegate 15:53:17 2026-08-21 EDT			5-day change	1st Jan Change
142.30 ^EUR	-11.45%		0.00%	+1.81%

10:10am	Alvotech Enters Licensing, Commercialization Deal for Two Biosimilars in US, Certain Asian Markets	MT
06:46am	Nibe a post-earnings winner on a rising Stockholm market, OMXS30 index up 0.9 percent	FW

All News

Mentions Relevance

08-20	Foresite Labs Appoints Dr. Jorge Reis-Filho to Chief Strategy Officer and Operating Partner; Joins Foresite Capital as Venture Partner	AQ
08-20	AstraZeneca PLC : Goldman Sachs reaffirms its Buy rating	ZD
08-19	AstraZeneca PLC : Deutsche Bank reiterates its Sell rating	ZD
08-19	AstraZeneca PLC : UBS reiterates its Buy rating	ZD
08-18	AstraZeneca - Update on eVOLVE-Lung02 Phase III trial of volrustomig plus chemotherapy in metastatic non-small cell lung cancer	AQ
08-17	Health Care Down on Growth Doubts - Health Care Roundup	DJ
08-17	UK Shares Start Week Downbeat; AstraZeneca Shares Data from Lung Cancer Trials	MT
08-17	European Stocks Close Lower in Monday Trading Despite Tech, Mining Stocks Rally	MT
08-17	BofA Notes AstraZeneca's Volrustomig Late-stage Study Fail; Buy Maintained	MT
08-17	ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated statistically significant and clinically meaningful improvement in PFS as 1st-line treatment of patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial	BU
08-17	TAGRISSO® (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO	BU
08-17	AstraZeneca Demonstrates Statistically Significant and Clinically Meaningful Improvements with TAGRISSO Plus Savolitinib in Saffron Phase III Trial	CI
08-17	AstraZeneca Discontinues EVOLVE-Lung02 Phase III Trial Of Volrustomig Plus Chemotherapy In Metastatic Non-Small Cell Lung Cancer	CI
08-17	HUTCHMED Announces ORPATHYS plus TAGRISSO Demonstrated Statistically Significant and Clinically Meaningful Improvements in Progression-Free and Overall Survival in MET-Driven EGFR-Mutated Lung Cancer	AQ
08-17	AstraZeneca PLC : JP Morgan remains its Buy rating	ZD
08-17	AstraZeneca Ends Phase Three Lung Cancer Drug Trial After Review -- Update	DJ
08-17	AstraZeneca Halts Lung Cancer Trial for Volrustomig; Reports Positive Data for Tagrisso Combo, Enhertu	MT
08-17	AstraZeneca halts lung trial as two cancer drugs show positive results	AN
08-17	AstraZeneca Reports Positive Results with Lung Cancer Drugs	MT
08-17	AstraZeneca Discontinues Phase 3 Lung Cancer Trial for Volrustomig Combination	MT
08-17	Triple news for AstraZeneca
08-17	AstraZeneca, Daiichi Sankyo's Enhertu Improves Progression-free Survival in Late-stage Lung Cancer Trial	MT
08-17	AstraZeneca ends one trial; Telecom Plus backs view	AN
08-17	AstraZeneca Ends Phase Three Lung Cancer Drug Trial After Review	DJ
08-17	AstraZeneca : Enhertu demonstrated statistically significant and clinically meaningful improvement in progression-free survival as 1st-line treatment of patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial	PU